166 related articles for article (PubMed ID: 17432221)
21. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds.
Czirr E; Weggen S
Neurodegener Dis; 2006; 3(4-5):298-304. PubMed ID: 17047371
[TBL] [Abstract][Full Text] [Related]
22. IGF-1 promotes beta-amyloid production by a secretase-independent mechanism.
Araki W; Kume H; Oda A; Tamaoka A; Kametani F
Biochem Biophys Res Commun; 2009 Feb; 380(1):111-4. PubMed ID: 19167357
[TBL] [Abstract][Full Text] [Related]
23. Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease.
Zetterberg H
Scand J Clin Lab Invest; 2009; 69(1):18-21. PubMed ID: 19199126
[TBL] [Abstract][Full Text] [Related]
24. Involvement of presenilins in cell-survival signalling pathways.
McCarthy JV
Biochem Soc Trans; 2005 Aug; 33(Pt 4):568-72. PubMed ID: 16042546
[TBL] [Abstract][Full Text] [Related]
25. Rac1 changes the substrate specificity of gamma-secretase between amyloid precursor protein and Notch1.
Boo JH; Sohn JH; Kim JE; Song H; Mook-Jung I
Biochem Biophys Res Commun; 2008 Aug; 372(4):913-7. PubMed ID: 18538664
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide gamma-secretase inhibitors.
Pu J; Kreft AF; Aschmies SH; Atchison KP; Berkowitz J; Caggiano TJ; Chlenov M; Diamantidis G; Harrison BL; Hu Y; Huryn D; Steven Jacobsen J; Jin M; Lipinski K; Lu P; Martone RL; Morris K; Sonnenberg-Reines J; Riddell DR; Sabalski J; Sun SC; Wagner E; Wang Y; Xu Z; Zhou H; Resnick L
Bioorg Med Chem; 2009 Jul; 17(13):4708-17. PubMed ID: 19443228
[TBL] [Abstract][Full Text] [Related]
27. Effects of sulindac sulfide on the membrane architecture and the activity of gamma-secretase.
Gamerdinger M; Clement AB; Behl C
Neuropharmacology; 2008 May; 54(6):998-1005. PubMed ID: 18359496
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease: from pathology to therapeutic approaches.
Jakob-Roetne R; Jacobsen H
Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
30. The role of amyloid beta peptide 42 in Alzheimer's disease.
Findeis MA
Pharmacol Ther; 2007 Nov; 116(2):266-86. PubMed ID: 17716740
[TBL] [Abstract][Full Text] [Related]
31. Purification, pharmacological modulation, and biochemical characterization of interactors of endogenous human gamma-secretase.
Winkler E; Hobson S; Fukumori A; Dümpelfeld B; Luebbers T; Baumann K; Haass C; Hopf C; Steiner H
Biochemistry; 2009 Feb; 48(6):1183-97. PubMed ID: 19159235
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of amyloid beta-peptide production by blockage of beta-secretase cleavage site of amyloid precursor protein.
Na CH; Jeon SH; Zhang G; Olson GL; Chae CB
J Neurochem; 2007 Jun; 101(6):1583-95. PubMed ID: 17542811
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
[TBL] [Abstract][Full Text] [Related]
34. Secretases as therapeutic targets for Alzheimer's disease.
Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG
Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746
[TBL] [Abstract][Full Text] [Related]
35. γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43.
Okochi M; Tagami S; Yanagida K; Takami M; Kodama TS; Mori K; Nakayama T; Ihara Y; Takeda M
Cell Rep; 2013 Jan; 3(1):42-51. PubMed ID: 23291095
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
Imbimbo BP; Panza F; Frisardi V; Solfrizzi V; D'Onofrio G; Logroscino G; Seripa D; Pilotto A
Expert Opin Investig Drugs; 2011 Mar; 20(3):325-41. PubMed ID: 21222550
[TBL] [Abstract][Full Text] [Related]
37. Expression of APP pathway mRNAs and proteins in Alzheimer's disease.
Matsui T; Ingelsson M; Fukumoto H; Ramasamy K; Kowa H; Frosch MP; Irizarry MC; Hyman BT
Brain Res; 2007 Aug; 1161():116-23. PubMed ID: 17586478
[TBL] [Abstract][Full Text] [Related]
38. Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments.
Kasturirangan S; Brune D; Sierks M
Biotechnol Prog; 2009; 25(4):1054-63. PubMed ID: 19572401
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
40. Platelet beta-secretase activity is increased in Alzheimer's disease.
Johnston JA; Liu WW; Coulson DT; Todd S; Murphy S; Brennan S; Foy CJ; Craig D; Irvine GB; Passmore AP
Neurobiol Aging; 2008 May; 29(5):661-8. PubMed ID: 17174011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
